ResMed Inc.

NYSE:RMD Rapport sur les actions

Capitalisation boursière : US$33.5b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ResMed Gestion

Gestion contrôle des critères 4/4

ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 11.42 years. total yearly compensation is $13.87M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $106.65M. The average tenure of the management team and the board of directors is 3.4 years and 8.8 years respectively.

Informations clés

Mick Farrell

Directeur général

US$13.9m

Rémunération totale

Pourcentage du salaire du PDG8.1%
Durée du mandat du directeur général11.4yrs
Propriété du PDG0.3%
Durée moyenne d'occupation des postes de direction3.4yrs
Durée moyenne du mandat des membres du conseil d'administration8.8yrs

Mises à jour récentes de la gestion

Recent updates

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Analyse de la rémunération des PDG

Comment la rémunération de Mick Farrell a-t-elle évolué par rapport aux bénéfices de ResMed?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$958m

Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Rémunération vs marché: Mick's total compensation ($USD13.87M) is about average for companies of similar size in the US market ($USD13.21M).

Rémunération et revenus: Mick's compensation has been consistent with company performance over the past year.

PDG

Mick Farrell (52 yo)

11.4yrs

Titularisation

US$13,868,641

Compensation

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Farrell
CEO & Chairman11.4yrsUS$13.87m0.32%
$ 106.6m
Peter Farrell
Founderno dataUS$680.27k0.060%
$ 19.9m
Brett Sandercock
Chief Financial Officer18.6yrsUS$3.11m0.067%
$ 22.3m
Robert Douglas
Special Advisorless than a yearUS$6.67m0.18%
$ 60.2m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.5yrsUS$3.31m0.015%
$ 5.0m
Amy Wakeham
Chief Investor Relations Officer1.3yrspas de donnéespas de données
Michael Rider
Chief Legal Officer1.1yrspas de données0.0077%
$ 2.6m
Jim Ellis
Chief Compliance Officer6.6yrspas de donnéespas de données
Yvonne-Katrin Pucknat
Chief Marketing Officerless than a yearpas de donnéespas de données
Vered Keisar
Chief People Officer3.4yrspas de donnéespas de données
Hemanth Reddy
Chief Strategy Officer9.7yrspas de donnéespas de données
Justin Leong
Chief Product Officer8.3yrspas de données0.019%
$ 6.3m

3.4yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: RMD's management team is considered experienced (3.4 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Farrell
CEO & Chairman11.4yrsUS$13.87m0.32%
$ 106.6m
Peter Farrell
Founder35.2yrsUS$680.27k0.060%
$ 19.9m
Richard Sulpizio
Independent Director19yrsUS$340.06k0.010%
$ 3.4m
Ronald Taylor
Lead Independent Director19.6yrsUS$372.56k0.014%
$ 4.7m
Jan De Witte
Independent Non-Executive Director5.3yrsUS$320.06k0.0039%
$ 1.3m
Harjit Gill
Independent Director5.8yrsUS$320.06k0.0049%
$ 1.6m
Carol Burt
Independent Director10.8yrsUS$360.06k0.010%
$ 3.4m
Karen Drexler
Independent Director6.8yrsUS$320.06k0.0052%
$ 1.7m
Desney Tan
Independent Director2.8yrsUS$320.06k0.0014%
$ 471.8k
John Hernandez
Independent Director2.8yrsUS$320.06k0.0014%
$ 471.8k

8.8yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: RMD's board of directors are considered experienced (8.8 years average tenure).